MedBlog

Cancer; Plastic Surgery

BIA-ALCL: 5 questions and answers about a cancer linked to breast implants

Cancer; Plastic Surgery

A person in a lab coat holding two breast implants, one in each hand.

In 2011, the Food and Drug Administration (FDA) identified a possible link between textured breast implants and a rare form of lymphoma known as breast-implant-associated anaplastic large-cell lymphoma, or BIA-ALCL.

Eight years later, in July 2019, the FDA requested that Allergan, the manufacturer of a type of textured implant, recall specific models from the U.S. market due to the risk of BIA-ALCL. Allergan has issued a worldwide recall of their BIOCELL textured implant products and related tissue expanders. The aggressive surface has been found to have six times greater risk for ALCL than other textured surfaces. This implant type represents less than 5% of the breast implants sold in the United States. 

Updated figures from the FDA reported 573 cases of BIA-ALCL worldwide and 33 deaths from the cancer. Of that number, 481 cases have been clearly attributed to Allergan Biocell implants, the agency said. In 13 of the deaths where the type of implant was known, 12 were linked to Allergan implants.

Textured surface implants are very rarely used at UT Southwestern, but if you already have them, it’s understandable you may be concerned about your potential risk for this disease. That’s why we’ve compiled this list of frequently asked questions and answers about BIA-ALCL. It is important to note that the FDA is not recommending removal of textured implants in woman with no symptoms.

“Timely recognition and intervention is key to curative treatment when it comes to BIA-ALCL. Waiting too long to get help can make BIA-ALCL more dangerous and treatment more difficult.”

Jeffrey Kenkel, M.D.
A diagram of a breast implant showing the placement of the implant, skin, fat, fibrous capsule, and the presence of lymphocytes within surrounding tissue.

Where in the breast has BIA-ALCL been found?

In the case studies reported in the literature, BIA-ALCL is usually found near the breast implant, contained within the fibrous scar capsule, and not in the breast tissue itself. The illustration below shows the location of the ALCL in these reports. In most cases, the ALCL cells were found in the fluid surrounding the implant (seroma) or contained within the fibrous scar capsule. Image courtesy of the U.S. Food & Drug Administration.